Oral mucositis (OM) is a painful and debilitating complication of cancer therapy that can adversely affect patients’ treatment regimens and quality of life.

While the mechanism of action of SalivaMAX™ is unknown it is hypothesized that the high concentration of calcium ions diffuses into the intracellular spaces in the epithelium and bathe the mucosal lesions. It is well known that calcium ions play an essential function in the inflammatory process, namely tissue repair and the blood clotting cascade. Phosphate ions also provide a comparable role in maintaining proper cellular health and healing damaged mucosa.


Markiewicz evaluated supersaturated calcium phosphate rinse compared to the standard of care, topical mouth solutions, in patients undergoing high dose chemotherapy. The supersaturated calcium phosphate group showed statistically significant improvements over the control group.5

Quinn provided a review of thirty studies and found that the majority (24) reported that a supersaturated calcium phosphate rinse was efficacious at reducing the mucositis grade and/or duration as well as the mucositis pain associated with the condition.2

This is the first published study to determine the efficacy of a supersaturated calcium phosphate oral rinse on patients with solid tumors (breast cancer) in response to chemotherapy-induced mucositis. Although this was a single sided study, the short time to elimination of mucositis was noteworthy: resolution of Grade 3 mucositis was an average of 4 days and Grade 2, 3.5 days.3

Taylor evaluated the cost benefit of using a supersaturated calcium phosphate rinse for treating oral mucositis in patients undergoing conditioning therapy for bone marrow transplantation (high dose chemo) and head and neck cancer (chemo and radiation therapy). The net savings of using a supersaturated calcium phosphate rinse over the standard of care was $5,582 and ranging $475 - $6,695, for each patient in addition to the positive clinical outcomes.4

In an ongoing clinical study using SalivaMAX™ at a Regional Cancer Center, the above percentage of patients found an improvement in their respective symptoms.

**Clinical Research:**

Not only has SalivaMAX™ reduced the severity of mucositis; it has pushed back the onset by almost one month. - JB (Oncology Clinician)

"Not only has SalivaMAX™ reduced the severity of mucositis, it has pushed back the onset by almost one month." - JB (Oncology Clinician)

Oral Mucositis

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain Swallowing</td>
<td>86%</td>
</tr>
<tr>
<td>Overall Oral Pain</td>
<td>67%</td>
</tr>
<tr>
<td>Sores in Oral Cavity</td>
<td>71%</td>
</tr>
<tr>
<td>Mouth Dryness</td>
<td>70%</td>
</tr>
</tbody>
</table>

In an ongoing clinical study using SalivaMAX™ at a Regional Cancer Center, the above percentage of patients found an improvement in their respective symptoms.

"Not only has SalivaMAX™ reduced the severity of mucositis; it has pushed back the onset by almost one month." - JB (Oncology Clinician)


Markiewicz evaluated supersaturated calcium phosphate rinse compared to the standard of care, topical mouth solutions, in patients undergoing high dose chemotherapy. The supersaturated calcium phosphate group showed statistically significant improvements over the control group.5

Quinn provided a review of thirty studies and found that the majority (24) reported that a supersaturated calcium phosphate rinse was efficacious at reducing the mucositis grade and/or duration as well as the mucositis pain associated with the condition.2

This is the first published study to determine the efficacy of a supersaturated calcium phosphate oral rinse on patients with solid tumors (breast cancer) in response to chemotherapy-induced mucositis. Although this was a single sided study, the short time to elimination of mucositis was noteworthy: resolution of Grade 3 mucositis was an average of 4 days and Grade 2, 3.5 days.3

Taylor evaluated the cost benefit of using a supersaturated calcium phosphate rinse for treating oral mucositis in patients undergoing conditioning therapy for bone marrow transplantation (high dose chemo) and head and neck cancer (chemo and radiation therapy). The net savings of using a supersaturated calcium phosphate rinse over the standard of care was $5,582 and ranging $475 - $6,695, for each patient in addition to the positive clinical outcomes.4


